AURKA and neoplasm: In recent years, interest has also grown in the direction of non-mitotic and kinase-independent AurkA roles that are now emerging as a route for both tumour onset and progression, and may partly account for the poor efficacy of AurkA inhibitors in clinical trials [28,29].